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INTRODUCTION
Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma that accounts for approximately 5% of all NHLs (1) . Despite recent improvements in therapy, most patients experience relapses and survive an average of approximately 5 years from the time of diagnosis (2) . Intensive chemotherapy regimens combined with anti-CD20 antibodies with or without autologous stem cell transplantation are widely used but not well-tolerated in elderly or unfit patients. Indeed, there is an urgent need for new targeted molecular approaches using novel compounds. New insights into the pathogenesis of MCL tumor cells have recently opened windows of opportunity for innovative targeted therapies (3, 4) . One of these new therapeutic approaches is to induce apoptosis via the intrinsic pathway and/or to overcome MCL cell resistance by antagonizing the anti-apoptotic Bcl-2 family proteins. This approach is prompted by several investigations demonstrating that the anti-apoptotic protein Bcl-2 is constitutively over-expressed in MCL and plays a major role in drug resistance (5, 6) . These findings highlight the potential of Bcl-2-targeted therapy in MCL.
Members of the Bcl-2 family are critical regulators of apoptosis and the interactions between pro-survival and pro-apoptotic members are major determinant of cell fate (7) . Structural and functional characteristics divide them into three subgroups: multidomain anti-apoptotic members (Mcl-1, Bcl-2, Bcl-x L , Bcl-W and A1), multidomain pro-apoptotic members (Bax and Bak) and BH3-only members (Bim, Bid, Bad, Bik, Puma and Noxa). In response to a wide range of derangement signals, BH3-only members are activated (8) . Certain BH3-only proteins, including Bim and Bid, are called activators because of their ability to activate Bax and Bak (9) . In contrast, the anti-apoptotic molecules antagonize cell death by sequestering either BH3-only proteins or multidomain pro-apoptotic members. The presence of Bax or Bak is required to mediate mitochondrial damage. First, these multi-domain pro-apoptotic family members have to be activated to oligomerize; subsequently, oligomers form pores in the mitochondrial outer membrane. The apoptotic cascade is frequently, if not always, altered in tumor cells, including MCL cells (3) .
ABT-737 is a new compound that selectively binds with high affinity to Bcl-2 and Bcl-x L (10) . ABT-737 displaces pro-apoptotic BH3-only from Bcl-2 or Bcl-x L , leading to activation of Bax and Bak and downstream caspases (9) . Due to the low affinity of ABT-737 for Mcl-1, high basal levels of Mcl-1 have been associated with ABT-737 resistance (11) (12) (13) (14) . Previous Ribrag (IRG, Villejuif, France). JEKO-1, MINO, REC-1, GRANTA-519 and JVM-2 were maintained in RPMI-1640 medium supplemented with 10 % FCS and 2 mM glutamine. UPN-1 was maintained in MEM α medium supplemented with 10 % FCS and 2 mM glutamine.
Primary MCL cells were obtained from patients treated in our institution who had provided their written informed consent and been diagnosed with de novo or relapsed MCL; diagnosis was confirmed according to the WHO classification (18) . MCL cells from blood or ascites were obtained following gradient density centrifugation using Ficoll-hypaque. For Western blotting analysis, MCL cells were purified with CD19-immuno-magnetic beads.
Antibodies (mAbs) and reagents.
Antibodies used in this study were: Anti-Bcl-2 (clone 124, Dako), Anti-Mcl-1 (S19, Santa Cruz Biotechnology) anti-caspase 3 (E-8,Santa Cruz Biotechnology), anti-Bik (N19, Santa Cruz Biotechnology), anti-Bcl-x L (BD Biosciences), anti-Actin (Chemicon), anti-Noxa (Alexis Coger), anti-Bax (clone 4F11, Immunotech), anti-Bim (Millipore),anti-Puma (Ab-1, Calbiochem), ABT-737 was kindly provided by Abbott Laboratories (Abbott Park, IL, USA).
Flavopiridol and cyrarabine-arabinoside were obtained from Sigma Aldrich. Bortezomib was kindly provided by Millenium Laboratory (Raleigh, NC, USA).
Flow cytometric analysis of apoptosis and Bax/Bak activation.
Cell death in MCL cell lines was assessed by Apo-2.7 staining. Cell death in primary MCL cells was assessed by both Apo-2.7 and CD19 staining combined with an analysis of altered cellular morphology (lower FSC). Flow cytometry analysis was performed on a FACSCalibur formaldehyde. The flow cytometry analysis was performed as above.
Research. 
RESULTS:

Sensitivity of MCL cell lines to ABT-737
The sensitivity of MCL cell lines to ABT-737 was investigated in normal culture conditions. After a 24-hour treatment, cell death was assessed using APO 2.7 staining (Fig 1A) . MINO and GRANTA-519 were highly sensitive to ABT-737 with a lethal dose (LD) 50 of 25 and 80 nM, respectively. In contrast, the four other MCL cell lines (JEKO-1, REC-1, UPN-1 and JVM-2) were resistant to ABT-737 (LD 50 > 8 µM). To determine the pathway by which ABT-737 induces apoptosis, the activation of caspases 9 and 3 was investigated. Cleavage of caspases 3 and 9 was detectable within 2 hours following treatment and was coupled to Bax and Bak activation demonstrating that apoptosis occurs via the intrinsic apoptotic pathway (Fig 1B and 1C) . Because ABT-737 selectively binds to anti-apoptotic Bcl-2 and Bcl-x L but not Mcl-1, the respective expression level of these proteins was investigated by Western blotting analysis (Fig 1 D) . MINO and GRANTA-519 both showed high expression of Bcl 
Sensitivity of primary MCL cells to ABT-737
ABT-737 induced apoptosis was also evaluated in primary MCL tumor cells from 13 patients.
Characteristics of patients are summarized in Supplemental Table. After 24 hours of ABT-737 treatment, cell death was quantified in the MCL cell compartment (CD19 positive cells) and a combined analysis of altered cellular morphology (lower FSC) was also performed (Fig 2A) .
ABT-737 induced apoptosis in MCL cells in 6 samples (with LD 50 s ranging from 15 to 150 nM), whereas 7 samples were classified as resistant to ABT-737 (median LD 50 not reached).
In 8 
ABT-737 triggered a rapid disruption of Bcl-2/ Bax and Bcl-2/Bik complexes
To determine the mechanism of action of ABT-737, the constitution of Bcl-2 complexes and their dynamic upon short time ABT-737 treatment were examined. For this purpose, Bcl-2 immunoprecipitations were realized after 2 hours ABT-737 treatment in the two sensitive cell lines. In untreated GRANTA-519 cells, Bcl-2 was associated with both the effector protein Bax and the BH3-only proteins Bim, Puma and Bik (Fig 3) . In contrast to GRANTA-519, MINO does not express Bim. In MINO, endogenous Bcl-2 was mainly associated with Bax, Puma and Bik. Of note, in both cells no interaction between Bcl-2 and Bak was found (result not shown). In GRANTA-519 cells, an examination of Bcl-2 heterodimers after a two-hours ABT-737 treatment showed a strong decrease of Bcl-2/Bax complexes and a very weaker decrease of both Bcl-2/Bik and Bcl-2/Puma complexes. Consistent with the strong decrease of Bcl-2/Bax complexes, there was an increase of Bax in the immunoprecipitate supernatant (Fig   3) . In MINO treated by ABT-737, an important decrease of both Bcl-2/Bax and Bcl-2/Bik complexes were observed. Similarly to GRANTA-519, a weak decrease of Bcl-2/Puma complex was found. Finally, while no disruption of the Bcl-2/Bim complex was observed after short time ABT-737 treatment in both cell lines, a longer treatment of eight hours led to a partial disruption of Bcl-2/Bim complexes (data not shown). This last result is in agreement with the fact that Bim displayed the highest affinity for Bcl-2.
Mcl-1 protects MCL cells against ABT-737-induced apoptosis
In Bcl-2 nor Bcl-x L levels were affected by flavopiridol exposure (Fig 4C) . Interestingly, the decrease of Mcl-1 level occurred rapidly, after 2 hours, and became undetectable after 4 hours of treatment with flavopiridol. This decrease was observed prior to caspase 3 cleavage, which was detected only after 6 hours of treatment (Fig 4D) . Fig 5A) . In contrast, bortezomib exposure does not modified Mcl-1 but induce a strong increase of the BH3-only Noxa protein (Fig 5B) . 
method) when both compounds were combined with ABT-737 in resistant JEKO-1 and JVM-2 ( Fig 5C) .
DISCUSSION
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